Tokai Pharmaceuticals, Inc. (NVUS)
(Delayed Data from NSDQ)
$2.59 USD
-0.14 (-5.13%)
Updated May 3, 2019 03:59 PM ET
After-Market: $2.58 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Eledon Pharmaceuticals, Inc. [NVUS]
Reports for Purchase
Showing records 1 - 5 ( 5 total )
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
Transformation Accomplished; Targeting Initiation of Up to 4 Clinical Trials
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
New Direction Marked by Initiation of Phase 2 Study With AT-1501 in ALS; Reiterate Buy With an Adjusted PT of $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
Where Do We Go From Here Now That OP0201 Still Needs POC?; Reit Buy and $2 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
We?re Hearing Baby Steps From Study C-006 Are Near; Reiterate Buy and $2 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Eledon Pharmaceuticals, Inc.
Industry: Medical - Drugs
Listen, OP0201 Could Be the Answer to Otitis Media; Initiate at Buy and $2 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
|